Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA fast tracks AstraZeneca’s diabetes drug Farxiga

The U.S. Food and Drug Administration granted fast track status for the development of AstraZeneca’s diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.

Read More »

Arbitration panel rules in favor of Lilly in complaint filed by Adocia

A Chicago-based arbitration panel ruled in favor of Eli Lilly and Company in a claim filed by Adocia S.A. over the companies’ prior collaboration on a rapid-acting insulin.

Read More »

Novo Nordisk and Mylan Battle Over Generic Versions of Victoza

Denmark’s Novo Nordisk filed a lawsuit in a Delaware district court against generic drugmaker Mylan.

Read More »

Cutting back on vegetable protein tied to unhealthy aging

Older adults who cut back on the amount of vegetable protein in their diets may be more likely to experience age-related health problems than their peers who increase the amount of plant protein they eat, a Spanish study suggests.

Read More »

AstraZeneca diabetes drug shows heart failure promise

AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.

Read More »

Liver disease related to obesity and diabetes rising in U.S.

The only liver disease becoming more widespread in the U.S. is one driven by obesity and diabetes – NAFLD – even as other liver disorder types linked to drinking or hepatitis become less common.

Read More »

The impact of technology on advancing diabetes care

Innovations in diabetes care go beyond new therapeutic classes. Pharmaceutical companies are continuing to invest in new technology to help improve diabetes treatment and patient adherence with progress ranging from artificial pancreases to smart insulin pens and pumps.

Read More »

Lexicon Posts Positive 52-Week Pooled Zynquista Data in Type 1 Diabetes

Shares of Texas-based Lexicon Pharmaceuticals shot up after the company announced positive 52-week cardiorenal data from a pooled analysis of the type 1 diabetes trials Tandem1 and Tandem2.

Read More »

Novo Nordisk’s new diabetes, obesity drugs lift sales outlook

Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.

Read More »

Eli Lilly tops profit estimates on boost from diabetes drugs

Eli Lilly and Co. beat analysts’ estimates for second-quarter 2019 profit and raised the company’s full-year earnings forecast, as higher sales of the diabetes drugs Trulicity and Basaglar offset competition for the erectile dysfunction treatment Cialis.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom